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P2Y6 receptor inhibition perturbs CCL2-evoked signalling in
human monocytic and peripheral blood mononuclear cells
Hinnah Campwala1, Darren W. Sexton2, David C. Crossman2 and Samuel J. Fountain1,*
ABSTRACT
The chemokine CCL2 serves to target circulating monocytes and
other leukocytes to tissue during innate immune responses, and
modulates the progression of chronic inflammatory disease through
activation of the receptor CCR2. Here, we show that co-activation of
the P2Y6 purinergic receptor (encoded by P2RY6) occurs when
THP-1 cells and human peripheral blood mononuclear cells sense
CCL2 through CCR2. Furthermore, P2Y6 receptor activation
accounts for ,80% of the intracellular Ca2+ signal evoked by
CCL2. Scavenging extracellular nucleotides with apyrase caused a
fourfold reduction in THP-1 sensitivity to CCL2, whereas inhibition
of CD39-like ectonucleotidases potentiated CCL2-evoked Ca2+
responses. Pharmacological inhibition of P2Y6 impaired CCL2-
evoked Ca2+ signalling and chemotaxis in peripheral blood
mononuclear cells and THP-1 cells. Furthermore, stable P2Y6
receptor knockdown (of twofold) in THP-1 cells impaired CCL2-
evoked Ca2+ signalling, chemotaxis and adhesion to TNFa-treated
HUVECs. We demonstrate that THP-1 cells rapidly secrete ATP
during signalling downstream of the CCL2–CCR2 axis and suggest
this might act as a mechanism for P2Y6 receptor co-activation
following CCL2 activation of the CCR2 receptor. The discovery that
P2Y6 receptor mediates leukocyte responsiveness to CCL2
represents a new mechanism by which to modulate CCL2 signals.
KEY WORDS: P2Y6, Chemokine, Monocyte, Purinergic signalling
INTRODUCTION
Chemokines are small secreted peptides that are crucial for the
homeostasis of the immune system and its activation during
immunity and chronic inflammatory disease. Chemokines operate
through activation of G-protein-coupled receptors expressed on
the target cells, including leukocytes, directing cells during
migration across microanatomical barriers and during interstitial
migration (Schabath et al., 2006; Tacke et al., 2007; Griffin et al.,
2010; Weninger et al., 2014). They can be subclassified into CC,
XC, CXC and CX3C chemokines based on the intramolecular
configuration and number of disulphide bonds. Chemokines
that act in a homeostatic capacity (e.g. CCL19, CCL21 and
CXCL13) are secreted constitutively and operate during immune
surveillance and tissue maintenance, whereas inflammatory
chemokines (e.g. CCL2, CCL5 and CX3CL1) are produced by
tissue de novo in response to tissue damage, infection and
inflammation (Cipollone et al., 2001; Namiki et al., 2002; Luther
et al., 2002; Spoettl et al., 2006; Serbina and Pamer, 2006). In
addition to its inflammatory role, CCL2 (also known as monocyte
chemoattractant protein 1, MCP-1) also participates in the egress of
monocytes from bone marrow during homeostasis and in the
absence of inflammation (Engel et al., 2008). Signalling by
inflammatory chemokines is associated with the early onset and
progression of several chronic inflammatory diseases, including
atherosclerosis, rheumatoid arthritis, diabetes and obesity, where
pronounced tissue leukocyte infiltration is a hallmark (Herder et al.,
2006; Zernecke and Weber, 2010; O’Boyle et al., 2012). Several
small-molecule inhibitors of chemokine receptors are in early and
clinical development as therapies (Bachelerie et al., 2014).
Recruitment of circulating monocytes to the arterial wall is
an important step in the onset and early progression of
atherosclerotic lesions. Animal models of atherosclerosis have
demonstrated that signalling by CCL2 and its cognate receptor
CCR2 contributes significantly to the magnitude of monocyte/
macrophage infiltrate and size of atherosclerotic lesion (Boring
et al., 1998; Gu et al., 1998; Veillard et al., 2005; Lutgens et al.,
2005). Classical CD14+/CD162 blood monocytes highly express
CCR2 (Weber et al., 2000), compared to lower expression in
CD14+/CD16+ monocyte subtypes. CCL2 is presented on the cell
surface of inflamed endothelium and participates in monocyte
recruitment by stimulating integrin-dependent firm adhesion and
transmigration of monocytes to the subendothelial space (Wang
et al., 1995; Ashida et al., 2001; Maus et al., 2002). Despite the
importance of signalling downstream of the CCL2–CCR2 axis,
the signal transduction mechanism involved in generating and
regulating CCL2-stimulated signals in monocytes remains poorly
delineated. CCR2 antagonists have shown varying therapeutic
efficacy in clinical trials, and alternative routes to regulating
CCL2 activity might prove attractive for future therapeutic
strategies (Struthers and Pasternak, 2010).
Leukocytes express a diverse repertoire of receptors for
extracellular signalling purines and pyrimidines. Purinergic
receptors include P2X (P2X1–7), which are ionotropic receptors
for ATP (North, 2002), and P2Y (P2Y1, P2Y2, P2Y4, P2Y6,
P2Y11, P2Y12, P2Y13 and P2Y14), which are metabotropic
receptors that are activated by ATP, ADP, UTP, UDP or UDP-
glucose depending on subtype (von Ku¨gelgen, 2006). Secreted
purines and pyrimidines can act in an autocrine and paracrine
fashion to relay signals through multiple purinergic receptors
expressed at the cell surface. The amount of secreted nucleotide
in the pericellular space is tightly regulated by a family of
ectonucleotide triphosphate diphosphohydrolases (E-NTPDases)
that includes CD39 (also known as ENTPD1), and serve to
terminate purinergic signalling through hydrolysis of nucleotide
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triphosphates and diphosphates to monophosphate forms (Dwyer
et al., 2007). We recently identified that THP-1 cells can secrete
ATP in response to chemical cues, and that this signalling
contributes to constitutive Ca2+ homeostasis (Sivaramakrishnan
et al., 2012). In neutrophils, ATP is secreted in response to
sensing f-Met-Leu-Phe (fMLP) and that this contributes to
chemotaxis (Chen et al., 2006).
Here, we investigate the interaction between the purinergic
signalling system and the functionality of CCL2 in THP-1 cells
and human peripheral blood mononuclear cells (PBMCs). We
have shown that P2Y6 activity regulates the magnitude of Ca2+
response evoked by signalling downstream of the CCL2–CCR2
axis and plays an important role in CCL2-evoked cellular
responses in THP-1 monocytic cells and PBMCs. We find that
the majority of Ca2+ signal generated following CCR2 activation
is via P2Y6. We suggest P2Y6 co-activation may occur following
CCL2 sensing in THP-1 cells and PBMCs via ATP secretion.
Antagonism of P2Y6 or gene silencing substantially attenuates
CCL2-evoked Ca2+ signals, chemotaxis towards CCL2 and
adhesion of CCL2-primed THP-1 cells to TNFa-treated human
umbilical vein endothelial cells (HUVECs). We identify P2Y6 as
a new and potent modulator of CCL2-dependent signalling in
human monocytic and peripheral blood mononuclear cells.
RESULTS
CCL2-receptor-mediated Ca2+ signalling is required
for chemotaxis
CCL2-evoked intracellular Ca2+ signals in THP-1 cells with a
half-maximal concentration of 1563 ng/ml (mean6s.e.m., n53;
Fig. 1A,B). Ca2+ signals evoked by CCL2 were abolished by
BMSCCR222 (IC5052.960.3 nM; n53) demonstrating that
CCL2-evoked signals are mediated through activation of CCR2
(Fig. 1C). CCL2-evoked Ca2+ signals were ablated by Bordetella
pertussis toxin (PTx; 100 ng/ml; n53) and U 73122 (5 mM;
n54) suggesting that the subsequent signal transduction events
involved in Ca2+ signal development following CCR2 activation
are dependent on Gai-type heterotrimeric G proteins and
phospholipase C (PLC) (Fig. 1D,E). Furthermore, THP-1 cell
migration towards CCL2 was inhibited by BMSCCR222, PTx
and following chemical chelation of cytoplasmic Ca2+ by BAPTA
AM (Fig. 1F). These data suggest that CCR2-mediated Ca2+
signals are essential for THP-1 cell migration towards CCL2.
Scavenging extracellular signalling nucleotides suppressed
CCL2-evoked Ca2+ signalling and cell migration
To determine the role of purinergic signalling in regulating
CCL2-evoked Ca2+ responses, we initially sought to investigate
Fig. 1. CCL2 receptor mediated Ca2+ signalling is required
for chemotaxis. (A) Representative Ca2+ transient evoked by
CCL2 in Fluo-4-loaded THP-1 cells. (B) Relationship between
peak Ca2+ response and CCL2 concentration in THP-1 cells
(n53). (C) Effect of the selective CCR2 antagonist BMSCCR222
on peak Ca2+ response to 50 ng/ml CCL2 expressed as a
percentage of control (no antagonists) in THP-1 cells (n53).
(D) Representative trace showing effect of PTx (100 ng/ml) on
CCL2-evoked Ca2+ responses in THP-1 cells (n53).
(E) Representative trace showing effect of PLC inhibition with
U73122 (5 mM) on CCL2-evoked Ca2+ responses in THP-1 cells
(n54). (F) Transwell assays showing the effect of PTx (100 ng/
ml), BMSCCR222 (BMS, 100 nM), U73122 (5 mM) and BAPTA-
AM (100 mM) (all n53) on THP-1 migration towards CCL2
(50 ng/ml lower chamber, 2 h). Fluo-4 signals are normalised to
the maximum Ca2+ response elicited by 40 mM digitonin.
*P,0.01 (ANOVA) versus vehicle control. Data are presented as
mean6s.e.m. All antagonists were pre-incubated for 30 min prior
to agonist challenge.
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the effect of modulating endogenous extracellular nucleotides
through application of CD39-like apyrase and through
pharmacological inhibition of E-NTPDases. Apyrase (2 U/ml)
attenuated CCL2-evoked Ca2+ signalling in both THP-1 monocytic
cells and human PBMCs (Fig. 2A,B), with peak responses
suppressed by 59%65 (n56) and 47%63 (mean6s.e.m., n53),
respectively. In THP-1 cells, the inhibition was marked by a
fourfold parallel rightward shift in the CCL2 concentration–
response curve for Ca2+ responses, indicating reduced efficacy of
CCL2 signalling during extracellular nucleotide scavenging
(Fig. 2C). To investigate the dependency of the response on
extracellular nucleotide triphosphates (NTPs; ATP, UTP) versus
nucleotide diphosphates (NDPs; ADP, UDP) we used two different
types of apyrases, one with a low NTPase:NDPase ratio and one
with a high NTPase:NDPase ratio. Both apyrase isoforms were
applied to give equal NTPDase activity, but the NDPase activity
would either be high or low dependent on the isoform. We
observed that enzymes with high NDPase activity produced greater
inhibition of CCL2 evoked Ca2+ signals (Fig. 2D). At 4 U/ml
NTPase activity, apyrase with high NDPase activity caused
,twofold more inhibition than low-NDPase activity apyrase
(Fig. 2D). These data suggest that the availability of extracellular
NDPs is a strong determinant of CCL2 signalling efficiency.
Apyrase treatment also suppressed THP-1 migration towards
CCL2 (Fig. 2E). Apyrase treatment had no effect on the cell
surface expression of CCR2 (supplementary material Fig. S1). In
reciprocal experiments, Ca2+ signals to sub-maximal
concentrations of CCL2 could be potentiated following E-
NTPDase inhibition (ARL 67156, 100 mM; 19%63; n59)
(Fig. 2F). The data suggest that the bioavailability of
extracellular nucleotides is a major determinant of CCL2
signalling efficacy.
P2Y6 activation amplifies CCL2-evoked Ca
2+ signalling in
THP-1 cells
As apyrase with high NDPase activity produced greater inhibition
of CCL2-evoked Ca2+ responses compared to apyrase with low
NDPase activity (Fig. 2D), we investigated the role of UDP/ADP-
activated P2Y receptors in facilitating CCL2 signalling. Candidate
receptors expressed in THP-1 cells and primary human monocytes
(data not shown) included P2Y1 (ADP), P2Y6 (ADP, UDP), P2Y11
(ADP), P2Y12 (ADP) and P2Y13 (ADP). Selective antagonism of
P2Y1, P2Y11, P2Y12 or P2Y13 with MRS 2179, NF 340, AR-C
66096 or MRS 2211, respectively, had no effect on CCL2-
generated Ca2+ signals or THP-1 migration towards CCL2 (data
not shown). In contrast, the selective P2Y6 receptor antagonist
MRS 2578 inhibited CCL2-evoked Ca2+ signals in THP-1 cells
(IC505418668 nM, mean6s.e.m., n53) (Fig. 3A,B) and in
PBMCs (Fig. 3C). MRS2578 treatment had no effect on the cell
surface expression of CCR2 (supplementary material Fig. S1).
P2Y6 inhibition revealed a persistent component of the CCL2-
evoked Ca2+ signal that was ,20% of maximum (Fig. 3B). The
Fig. 2. Effect of modulating extracellular nucleotides on THP-1 and human PBMC responses to CCL2. Representative traces showing effect of the
nucleotide-scavenging enzyme apyrase on the CCL2-evoked Ca2+ signal in THP-1 cells (A) and human PBMCs (B). (C) Apyrase (2 U/ml) induced a rightwards
parallel shift in the CCL2 concentration–response relationship for peak Ca2+ responses in THP-1 cells (n53). (D) Effect of apyrase enzymes with equal NTPase
activity but high or low NDPase activity on peak Ca2+ responses evoked by CCL2 (50 ng/ml) expressed as a percentage of the response in the absence of
enzyme (n53; *P,0.05, Students t-test). Enzyme units refers to NTPase activity. (E) Apyrase (2 U/ml) suppresses THP-1 chemotaxis towards CCL2 (50 ng/ml
lower chamber, 2 h) in transwell migration assays (n55; *P,0.01, ANOVA). (F) Representative trace showing that the response to submaximal
concentrations of CCL2 is potentiated following E-NTPDase inhibition (ARL67156, 100 mM; n59). Fluo-4 signals are normalised to maximum Ca2+ response
elicited by 40 mM digitonin. Data are presented as mean6s.e.m. All antagonists were pre-incubated for 30 min prior to agonist challenge.
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resistant component was abolished by selective CCR2 antagonism
with BMSCCR222 (Fig. 3A). These data suggest that engagement
of P2Y6 accounts for ,80% of the maximal Ca2+ response to
CCL2 and that activation of the CCR2 receptor alone, although
indispensible, generates only 20% of the maximal response. Ca2+
responses to UDP were unaffected by CCR2 inhibition (data not
shown) suggesting P2Y6 activity does not reciprocate a
dependency on CCR2 activity. CCL2-evoked Ca2+ responses in
PBMCs were also antagonised by MRS2578 (34%69; n53
donors, P,0.05). Further evidence for CCL2-dependency upon
P2Y6 activity was sought by desensitizing P2Y6 with
supramaximal concentrations of ADP or UDP agonist prior to
CCL2 application. UDP elicited a modest sustained Ca2+ response
(Fig. 3D), characteristic of the slow desensitization kinetics of
P2Y6. Application of 3 mM UDP or ADP desensitized subsequent
nucleotide responses by 68%610 and 40%68 (n53–5),
respectively (Fig. 3D). CCL2 responses were attenuated by UDP
(25%64; n55) and ADP (27%65; n53) when applying the same
desensitization protocol (Fig. 3E). No additional response over
CCL2 alone was observed when CCL2 and UDP were co-applied
(Fig. 3F). These data suggest P2Y6 serves to amplify the CCL2
response through co-activation following CCL2 sensing in
monocytes. Our observations in Ca2+ signal experiments were
mirrored in functional assays whereby P2Y6 inhibition reduced
migration to CCL2 in both THP-1 cells (82%62; n54) (Fig. 3G)
and PBMCs (82%65; n53 donors) (Fig. 3H).
Fig. 3. P2Y6 receptor antagonism and desensitization suppresses Ca
2+ signalling downstream of the CCL2–CCR2 axis. (A) Representative traces
demonstrating the dependency of CCR2 and P2Y6 for CCL2-evoked Ca
2+ signalling in THP-1 cells. Traces shown are for responses in the absence of
antagonist (control), following selective P2Y6 inhibition (MRS2578, 1 mM) and following inhibition of P2Y6 and CCR2 receptors [MRS2578 + BMSCCR222
(BMS), 100 nM]. (B) Concentration–response relationship showing inhibitory action of MRS2578 on peak Ca2+ responses to CCL2 (50 ng/ml). The MRS2578-
resistant component of ,20% accounts for CCR2 activity (n53). (C) Representative trace showing inhibition of CCL2-evoked Ca2+ signalling in human PBMCs
following P2Y6 inhibition (MRS2578, 1 mM) (n53). (D) Representative traces showing desensitization of UDP (3 mM)-evoked Ca2+ response in subsequent
applications 10 min apart. (E) Representative trace showing effect of UDP (3 mM) pre-application (as in D) on CCL2 (50 ng/ml)-evoked Ca2+ response in THP-1
cells. (F) Representative traces showing lack of synergy between CCL2 (50 ng/ml) and UDP (30 mM) as revealed by co-application experiments. P2Y6
receptor inhibition (MRS2578, 1 mM) inhibition of THP-1 cell (G) and PBMC (H) chemotaxis towards CCL2 (50 ng/ml lower chamber, 2 h) in transwell migration
assays (n53–4). Fluo-4 signals are normalised to the maximum Ca2+ response elicited by 40 mM digitonin. **P,0.01 (ANOVA). Data are presented as
mean6s.e.m. All antagonists were pre-incubated for 30 min prior to agonist challenge.
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P2Y6 engagement is not required for fMLP signalling
To rule out a generalized role of P2Y6 engagement in amplifying
Ca2+ responses to other chemotactic peptides, we investigated the
effect of P2Y6 inhibition on Ca
2+ responses and cell migration
mediated by fMLP. Nanomolar fMLP elicited concentration-
dependent Ca2+ responses in THP-1 cells (Fig. 4A). Responses
were insensitive to maximal concentrations of MRS2578
(Fig. 4B), although they were attenuated by apyrase (61%66,
mean6s.e.m., n53) (Fig. 4C,D). Cell migration towards fMLP
was also insensitive to MRS2578 but inhibited by apyrase
(Fig. 4E). These data exclude a role of P2Y6 in fMLP-dependent
signalling in monocytic cells but highlight a potential role for
other P2 receptor subtypes.
P2Y6-knockdown THP-1 cells display impaired CCL2-evoked
migration and adhesion to TNFa-treated HUVECs
To support our pharmacological data, we generated stable P2Y6-
knockdown THP-1 lines through lentivirus-mediated shRNA
delivery. From a screen of five shRNA clones, the best
performing clone achieved a 50%65 (mean6s.e.m., n53)
reduction in the functional Ca2+ response to UDP compared to
scrambled shRNA-expressing cells (Fig. 5A). Clone 5 (Fig. 5A)
showed a twofold knockdown of P2Y6 (P2RY6) mRNA
transcripts and was used in all subsequent experiments. P2Y6
knockdown did not alter the level of CCR2 mRNA transcripts
(data not shown), and had no effect on the cell surface expression
of CCR2 (supplementary material Fig. S1). P2Y6 protein levels
were not probed owing to lack of specific P2Y6 antibodies (Yu
and Hill, 2013). P2Y6 knockdown THP-1 cells displayed a
marked reduction (20%61; n53) in the peak Ca2+ response to
CCL2 versus scrambled shRNA counterparts (Fig. 5B). P2Y6-
knockdown cells also displayed reduced migration towards CCL2
(Fig. 5C). CCL2 participates in early monocyte recruitment
events such as adhesion to endothelium (Gerszten et al., 1999;
Maus et al., 2002; Hiraoka et al., 2004). To this end, we sought to
test the impact of P2Y6 receptor knockdown on CCL2-stimulated
THP-1 adhesion to vascular endothelium. CCL2 priming of THP-
1 cells enhanced adhesion to both non-inflamed and inflamed
(TNFa; 10 ng/ml, 5 h) HUVEC monolayers (Fig. 5D–F).
Adhesion stimulated by CCL2 could be abolished by CCR2
antagonism with BMSCCR222 (Fig. 5D,E). P2Y6 knockdown
had no significant effect on THP-1 adhesion to non-inflamed
endothelium (Fig. 5F) but caused a substantial inhibition of
adhesion to inflamed cells (Fig. 5G). Adhesion to TNFa-treated
HUVECs could also be inhibited by MRS2578 (78%615; n58)
(Fig. 5F). Taken together, these data support a role of P2Y6 in
monocyte function associated with inflammation.
CCL2-stimulated ATP secretion in THP-1 cells
We have previously demonstrated that THP-1 cells can secrete
ATP in response to chemical cues (Sivaramakrishnan et al., 2012;
Campwala and Fountain, 2013). It is, therefore, plausible that
ATP secreted in response to CCL2 could liberate ADP required to
activate P2Y6 through cell surface E-NTPDase activity. We
undertook experiments using reverse-phase high-pressure liquid
chromatography (HPLC) to determine the species of nucleotide
secreted from THP-1 cells following CCL2 challenge, to gain
evidence for release of ADP or UDP P2Y6 ligands, or UTP and
ATP precursor molecules. Our HPLC methodology allowed
detection of ATP, UTP, ADP and UDP standards with a
detection threshold close to 1 mM. Despite this, ATP was the
only nucleotide that showed increased secretion from THP-1 cells
challenged with CCL2. ADP was rarely detected in substantial
amounts. Extracellular ATP increased in a time-dependent fashion
following CCL2 challenge (Fig. 6A). Evidence for CCL2-evoked
ATP secretion was supported by luciferin-luciferase assays. In
these experiments, CCL2 evoked a transient elevation in
extracellular ATP with a peak amplitude of 10136108 nM
(mean6s.e.m., n57) (Fig. 6B,C). Ca2+ responses in THP-1 cells
evoked by 1 mM exogenous ATP were antagonized by P2Y6
inhibition (31%61, n53) (Fig. 6D) demonstrating the capacity of
secreted ATP, at the levels detected, to activate P2Y6. Without a
direct measure of UDP secretion, we cannot exclude the possibility
that its secretion is below the detection limits of our HPLC
methodology. UDP acted at the human P2Y6 receptor stably
expressed in 1321N1 cells with a half-maximal concentration of
2363 nM, compared to 3.460.2 mM for ADP (data not shown).
We propose that agonist-induced nucleotide secretion is a possible
Fig. 4. The fMLP-evoked Ca2+ response
and chemotaxis are not dependent on P2Y6
receptor activity in THP-1 cells.
(A) Representative Ca2+ transients evoked by
various concentrations of fMLP.
(B) Representative paired trace showing the
lack of effect on fMLP (1 mM)-evoked Ca2+
responses following P2Y6 receptor inhibition
(MRS2578, 1 mM). (C) Trace showing
inhibitory action of apyrase (2 U/ml) on the
magnitude of response evoked by fMLP
(1 mM) with average data shown in D. Apyrase
(2 U/ml), but not MRS2578 (1 mM), inhibits
THP-1 cell chemotaxis towards fMLP (1 mM
lower chamber, 2 h) in transwell migration
assays (n54). Fluo-4 signals are normalised to
the maximum Ca2+ response elicited by 40 mM
digitonin. ***P,0.01 (ANOVA). Data are
presented as mean6s.e.m. All antagonists
were pre-incubated for 30 min prior to
agonist challenge.
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mechanism underlying co-activation of P2Y6 following CCR2
activation.
DISCUSSION
In this study, we have identified a new signalling interaction
between the CCR2 receptor (for CCL2) and the P2Y6 receptor
(for ADP and UDP) in THP-1 monocytic cells and human
PBMCs. Our results clearly indicate that, although CCL2-
mediated Ca2+ responses show an absolute requirement for
CCR2, subsequential activation of the P2Y6 receptor serves to
substantially amplify the Ca2+ signal. This interaction between
CCR2 and P2Y6 receptor activity is essential for THP-1
chemotaxis and adhesion to inflamed vascular endothelium in
response to CCL2. The activity of P2Y6 appears to differentially
regulate the response to chemotactic peptides as inhibition of
P2Y6 or silencing its expression with shRNAs in THP-1 cells
impairs the responses to CCL2, but the responsiveness of these
cells to fMLP is independent of P2Y6 receptor activity.
However, our study does support a role of extracellular
signalling nucleotides in controlling Ca2+ responses and
cellular migration to fMLP, as apyrase impairs both these
processes. The data support previous studies showing
fMLP-stimulated chemotaxis in human neutrophils is impaired
by apyrase treatment (Chen et al., 2006). Our work also supports
the hypothesis that CCR2 receptors couple to Gai-type
heterotrimeric G proteins (Chen et al., 2006), and that Ca2+-
evoked signalling is mediated through PLC activity. Although
U73122 cannot discriminate between PLC isoforms, the
coupling is likely through interaction of Gbc subunits with
PLCb isoforms (Park et al., 1992). Indeed, we observed that the
Gbc antagonist gallein inhibits CCL2-stimulated chemotaxis in
THP-1 cells (data not shown). What is clear from our study is
that CCL2-evoked Ca2+ signals are essential for THP-1
chemotaxis towards CCL2 as inhibition of Gai, PLC and
chemical buffering of intracellular Ca2+ with BAPTA all
substantially attenuate THP-1 cell migration towards CCL2.
The activity of phospholipase enzymes and the generation of
Ca2+ signals are crucial for leukocyte movement (Cathcart,
2009). Indeed, localized Ca2+ signalling events at the leading
edge of migrating leukocytes is important for the organization of
actin and focal complex assembly during the formation of
pseudopods (Mishra et al., 2008). In transwell migration assays,
we observed that chelating intracellular Ca2+ with BAPTA-AM
inhibited the level of basal THP-1 migration. Changes in
Fig. 5. P2Y6-knockdown THP-1 cells have
impaired CCL2-evoked Ca2+ signalling,
chemotaxis and adhesion to TNFa-treated
HUVECs. (A) Comparison of UDP (30 mM)-
evoked Ca2+ responses in THP-1 stable lines
expressing scrambled shRNA or P2Y6-
targeted shRNA derived from 5 different
clones (clone 1–5) (n53). Functional
knockdown of UDP responses are revealed in
clones 2–5. (B) Representative traces
showing the attenuated Ca2+ response to
CCL2 in P2Y6-knockdown (P2Y6
KD) cells.
(C) Impaired chemotactic response to CCL2
(50 ng/ml lower chamber, 2 h) observed in
transwell migration assays for P2Y6
KD cells
versus scrambled THP-1 cells (n54).
(D) CCL2 priming (50 ng/ml, 45 min) of THP-1
cells stimulated adhesion to non-inflamed
HUVECs. P2Y6 inhibition (MRS2578, 1 mM)
abolished CCL2-evoked adhesion (n520).
(E) In inflamed HUVECs (TNFa, 10 ng/ml,
5 h), CCL2 priming (50 ng/ml, 45 min) of
THP-1 cells also stimulated adhesion that
could be blocked by pre-treatment with either
BMSCCR222 (100 nM) or MRS2578 (1 mM)
(E) (n58 for both). (F) P2Y6 knockdown
causes variable adhesion of CCL2-primed
THP-1 cells to TNFa-treated HUVECs as
compared for scrambled (scram) and P2Y6-
knockdown lines (n56). (G) CCL2-primed
P2Y6-knockdown THP-1 cells display
impaired adhesion to inflamed HUVECs
(TNFa, 10 ng/ml, 5 h) versus scrambled
counterparts (n58). P2Y6
KD refers to clone 5
(as shown in A) throughout. Fluo-4 signals
are normalised to the maximum Ca2+
response elicited by 40 mM digitonin.
**P,0.01, *P,0.05 (ANOVA). Data are
presented as mean6s.e.m. All antagonists
were pre-incubated for 30 min prior to
agonist challenge.
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cytoplasmic Ca2+ are important for cell polarization and motility
during chemotaxis (Wei et al., 2012), but also influence random
cell migration where spontaneous Ca2+ events are believed to
play a role (Lee et al., 2012).
In experiments involving apyrase, we demonstrate that
nucleotide scavenging causes an approximate fourfold shift in
CCL2 potency during Ca2+ signalling. The attenuation is
surmounted by higher CCL2 concentrations, but the activation
threshold for CCL2 in apyrase-treated THP-1 cells is .50 ng/ml
versus 5 ng/ml for untreated cells. Based on our data, apyrase
treatment might render monocytic cells non-responsive to the
small, but substantially elevated, concentrations of plasma CCL2,
as detected in sepsis (Bossink et al., 1995), sarcoidosis
(Hashimoto et al., 1998), subclinical atherosclerosis (Deo et al.,
2004) and type II diabetes (Piemonti et al., 2009). In reciprocal
experiments, increasing the pericellular availability of nucleotide
triphosphate and diphosphate by E-NTPDase inhibition with
ARL67156 potentiated responses to CCL2. These data clearly
demonstrate that the levels of extracellular nucleotides modulate
how monocytic cells and PBMCs respond to CCL2 by controlling
the detection threshold of CCL2. In an in vivo setting, this would
suggest CCR2+ leukocytes in environments of high E-NTPDase
activity would have dampened responses to CCL2. The
prototypical E-NTPDase CD39 plays a strategic role in
calibrating the magnitude, duration and chemical nature of
signalling purines and pyrimidine signals presented to immune
cells (Antonioli et al., 2013), and is highly expressed by
regulatory T cells that decrease the formation of atherosclerotic
lesion (Borsellino et al., 2007; Dinh et al., 2012). The anti-
inflammatory activity of CD39 is attributed to limiting
extracellular ATP accumulation, which suppresses production
and release of pro-inflammatory cytokines, such as interleukin
(IL)-1b, IL-6, IL-18 and TNFa from leukocytes (Reutershan
et al., 2009; Le´vesque et al., 2010). The activity of CD39
expressed by resting vascular endothelium is important for
maintaining the antithrombotic low ATP and ADP environment
(Packham and Mustard, 2005; Fung et al., 2009). Our study
reveals an additional new anti-inflammatory role for CD39-like
E-NTPDases by limiting the availability of P2Y6 ligand and
suppressing signalling downstream of the CCL2–CCR2 axis.
We have demonstrated the ability of human THP-1 cells to
secrete ATP in this study and in previous studies
(Sivaramakrishnan et al., 2012; Campwala and Fountain, 2013).
ATP secretion in response to sensing chemoattractants might be a
common mechanism in leukocytes, as human neutrophils secrete
ATP in response to fMLP (Chen et al., 2006). In this study, we
detected an elevation in ATP of ,1 mM following exposure to
CCL2. Our bulk-phase measurements are likely to underestimate
the pericellular concentration of extracellular ATP. Indeed,
pericellular measurement of ATP secretion evoked by fMLP in
neutrophils reveals levels close to 30 mM (Chen et al., 2006). Our
data also supports a role for extracellular nucleotides in fMLP-
mediated responses as apyrase impairs fMLP-evoked Ca2+ signals
and chemotaxis. However, our study does not support a role for
P2Y6. Chen et al. (Chen et al., 2006) suggest a role for the P2Y2
receptor for ATP and/or UTP in supporting fMLP signalling in
neutrophils, which do not express P2Y6. We show that P2Y6
plays a substantial role in amplifying signalling downstream of
the CCL2–CCR2 axis and have ruled out the involvement of
other P2Y receptors (based on selective antagonism), although we
cannot rule out a contribution of P2Y2 in amplifying the CCL2
response. Our data suggest that the contribution of non-P2Y6
purinergic receptors would be small based on the magnitude of
inhibition with MRS2578. In addition, we observed that
MRS2578 inhibits CCL2-evoked Ca2+ signals to a lesser extent
in PBMCs than in THP-1 cells. We suggest that although CCR2 is
the cognate receptor for CCL2, the PBMC fraction will contain a
mixed population of cells, some of which might not express P2Y6
or might express P2Y6 to a varied degree compared to in THP-1
cells. Exploring the functional interaction between P2Y6 and
CCL2 in leukocyte subtypes is therefore an important future
work.
Several important questions arise from this study. Activation of
CCR2 by CCL2 and N-formyl peptide receptors by fMLP both
raise cytoplasmic Ca2+ by pertussis-toxin-sensitive mechanisms
(Krause et al., 1985), and Ca2+ responses and chemotaxis evoked
by both are substantially impaired by apyrase. The suggestion
here is that fMLP might cause ATP release in human monocytes
as in neutrophils (Chen et al., 2006). Despite these similarities,
CCL2 responses are highly dependent upon P2Y6 receptor
Fig. 6. CCL2-coupled ATP secretion. (A) CCL2-stimulated ATP
secretion from THP-1 cells detected by HPLC. Representative traces
show HPLC analysis of THP-1-conditioned buffer following no stimulation
(buffer alone) or collected immediately after (CCL2 i) or 2 min after
(CCL2 ii) CCL2 (50 ng/ml) stimulation. Peak retention and amplitude are
shown in comparison to a 1 mM ATP standard. (B) ATP content in THP-1-
conditioned buffer collected before and after CCL2 (50 ng/ml)
stimulation as quantified by luciferase bioluminescence (n57 for each
time point). (C) Mean peak ATP secreted following CCL2 stimulation
quantified by luciferase bioluminescence (n57). (D) Representative
traces showing the suppression of the Ca2+ response evoked by 1 mM
exogenous ATP following P2Y6 receptor inhibition (MRS2578, 1 mM).
Fluo-4 signals are normalised to the maximum Ca2+ response elicited by
40 mM digitonin. ***P,0.01 (ANOVA). Data are presented as
mean6s.e.m. All antagonists were pre-incubated for 30 min prior to
agonist challenge.
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activation, although fMLP responses are independent of P2Y6
activity. A possible explanation for this might be that CCR2,
P2Y6 and the ATP release site are in close proximity. This might
be an important spatial arrangement as CD39-like activity would
mean that secreted ATP would have a very short half-life and
would be unlikely to diffuse significantly across the cell surface
to target receptors. One would therefore assume the formyl
peptide receptors and P2Y6 are not in close proximity or that
fMLP does not evoke secretion of P2Y6 receptor ligand.
Localised association of CCR2 and P2Y6 might be important
for amplifying local external CCL2 signals, enabling cell
orientation and migration in chemotactic fields. A further
question raised by this study is how CCR2 activation couples
to ATP secretion. Several routes have been proposed for ATP
release, including lysosome secretion (Sivaramakrishnan et al.,
2012), connexin, pannexin and hemichannels (Huang et al., 2007;
Kang et al., 2008), and ion channels (Hisadome et al., 2002;
Suadicani et al., 2006; Romanov et al., 2008). Understanding how
CCR2 activation couples to ATP secretion might also provide
targets to suppress CCL2-evoked signals. Our data suggest that
targeting P2Y6 would impede CCL2-dependent tissue recruitment
of monocytes at two keys steps, chiefly monocyte adhesion to
inflamed vascular endothelium and monocyte migration. In
addition, our data reveal a varying dependency on P2Y6 for
CCL2-mediated THP-1 adhesion to non-inflamed versus
inflamed HUVECs. This is an intriguing observation but is
difficult to provide a concise explanation. We suggest that P2Y6
receptor engagement serves to amplify the CCL2 signal;
however, residual CCR2-dependent signalling can still occur
when P2Y6 activity is pharmacologically inhibited. This might
suggest that the magnitude of CCL2-evoked signalling in the
absence of P2Y6 is sufficient to allow THP-1 adhesion to non-
inflamed, but not inflamed, HUVECs.
MATERIALS AND METHODS
Chemicals and reagents
All chemicals were purchased from Sigma-Aldrich (UK) with the
exception of BMSCCR222, BAPTA AM, MRS2578, ARL67156, AR-
C66096 and Bordetella pertussis toxin (PTx; Tocris Bioscience, UK),
MRS2179, MRS2211 (Abcam Biochemicals, UK), CCL2, TNFa and
Fluo-4 AM (Life Technologies, UK), and Calcein AM (Santa Cruz
Biotechnology, Germany). THP-1 and HEK 293T cells were procured
from the European Collection of Cell Cultures (ECACC), and HUVECs
from Caltag Medsystems (UK). Human 1321N1 P2Y6 stable cells were a
kind gift from Jens Leipziger (Aarhus University, Denmark). Compounds
used did not induce toxicity under assay conditions as determined by a
Trypan Blue exclusion assay or lactate dehydrogenase (LDH) release
assay.
Cells
THP-1 cells (human acute monocytic leukaemia) were cultured in RPMI
1640 medium with 2 mM L-glutamine, 10% (v/v) heat-inactivated foetal
bovine serum (HI-FBS), and 50 IU/ml penicillin and 50 mg/ml
streptomycin. Cultures were maintained between 16105 and 16106
cells/ml. Early passage HUVECs were cultured to confluency in
endothelium cell growth medium (PromoCell GmbH, Germany).
1321N1 hP2Y6 stable cells were transfected as described previously
(Communi et al., 1996) with recombinant pcDNA3 plasmid encoding
human P2Y6 and were grown in DMEM medium supplemented with 10%
(v/v) HI-FBS and 0.4 mg/ml G418. All cultures were maintained at 37 C˚
in a humidified 5% CO2 incubator.
Isolation of PBMCs
Peripheral venous blood was collected from healthy human volunteers in
sodium citrate solution (1:10 volumes). Blood was diluted 1:1 with
Dulbecco’s phosphate-buffered saline (dPBS) before being transferred to
Accuspin tubes (containing Histopaque 1077; Sigma-Aldrich, UK) for
centrifugation at 1000 g for 10 min. The resultant buffy layer was
carefully removed and washed three times with dPBS (1:1 volumes),
centrifuging at 250 g for 10 min in between washes before final
collection of PBMCs. Use of blood from healthy volunteers was
approved by the Faculty of Medicine and Health Sciences Research
Ethics Committee, University of East Anglia (UK).
Intracellular Ca2+ measurements
For intracellular Ca2+ measurements with THP-1 cells, 106 THP-1 cells/
ml were loaded for 1 h at 37 C˚ with 2 mM Fluo-4 AM in SBS buffer
containing: 130 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 1.5 mM CaCl2,
8 mM D-glucose, 10 mM HEPES pH 7.4, plus 0.01% (w/v) pluronic
acid. Cells were re-suspended at 106 cells/ml in SBS. Fluo-4 AM
fluorescence (494 nm excitation; 516 nm emission), was sampled at
room temperature at 1-s intervals using a Hitachi F-2000 fluorescence
spectrophotometer. Cells in a quartz cuvette were continuously agitated
by means of a magnetic stirrer. Maximum fluorescence (Fmax) signals
were generated by the addition of 40 mM digitonin. Ca2+ responses to
drugs were expressed as a percentage of Fmax. Experiments were
performed at room temperature (22–25 C˚). Intracellular Ca2+
measurements were with human PBMCs performed as described above
using 26107 cells/ml loaded in 4 mM Fluo-4 AM.
Transwell migration assays
Transwell migration assays with THP-1 cells were performed in 24-well
plates using polyethylene terephthalate (PET) membrane transwell
inserts with 3-mm pores (BD Biosciences, UK). THP-1 cells (106) in
RPMI without serum were added to upper chambers, and 50 ng/ml
CCL2 or 1 mM fMLP or vehicle were added to lower chambers.
Compounds were added to upper wells as appropriate. Cell migration
was allowed to progress for 2 h at 37 C˚ in a humidified 5% CO2
incubator. Inserts were washed twice in ice-cold dPBS and fixed with
220 C˚ methanol. Upper chambers were swabbed and cells stained with
0.5% (w/v) Crystal Violet. Migrated cells were scored using an
Olympus CKX41 inverted microscope equipped with a Leica digital
camera. Cell migration was assessed by calculating the chemotactic
index (CI) by dividing the number of cells migrating in response to
treatment by the number of spontaneously migrated cells. Transwell
migration assay with human PBMCs were performed as described above
using 16106 cells/ml in Hanks balanced salt solution containing 2.9 g/l
HEPES.
HUVEC adhesion assay
HUVECs were plated onto wells of a black, clear-bottomed 96-well plate
and allowed to form confluent monolayers over 48 h at 37 C˚ in a
humidified 5% CO2 incubator. HUVEC monolayers were washed once
with SBS buffer prior to pre-treatment with TNFa (10 ng/ml) or vehicle
(SBS buffer) for 5 h at 37 C˚. During this incubation phase, THP-1
(16106 cells/ml) were loaded with 5 mM Calcein-AM in SBS buffer plus
0.01% (w/v) pluronic acid for 1 h at 37 C˚. Following loading, THP-1
cells were re-suspended to 106 cells/ml in SBS buffer and primed with
CCL2 (50 ng/ml) or vehicle (SBS buffer) for 45 min at 37 C˚. THP-1
cells were washed once before addition to washed HUVEC monolayers,
allowing cells to adhere for 1 h at 37 C˚ in a humidified 5% CO2
incubator. Non-adhered cells were aspirated and adhered cells were
washed twice with SBS buffer before reading the fluorescence intensity
(496 nm excitation; 516 nm emission).
Luciferase–luciferin assay for nucleotide release
Release of nucleotides from THP-1 cells was assayed by means of an
ATP bioluminescence assay kit (HSII kit, Roche, UK). THP-1 cells (106
cells/ml in SBS buffer) were challenged with CCL2 (50 ng/ml) at room
temperature prior to sampling (60 ml). Cells were immediately
sedimented at 4 C˚ and 20,000 g and clarified samples were mixed 1:1
with luciferase reagent before luminescence measurements were made
using a Modulus Luminometer (Turner BioSystems, USA) with a 7-s
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integration time. Experiments were performed at room temperature
(22–25 C˚).
Ion-pair reverse-phase HPLC for nucleotide release
HPLC detection of nucleotides was performed using a Supercosil LC-18-
T column (Sigma-Aldrich, UK) equilibrated with 10 column volumes of
Buffer B (organic phase) and 30 volumes of Buffer A (mobile phase).
Buffer A consisted of 39 mM K2HPO4, 26 mM KH2PO4 and 4 mM
tetrabutylammonium hydrogen sulfate, pH 6.0. Buffer B consisted of
39 mM K2HPO4, 26 mM KH2PO4 and 25% (v/v) methanol, pH 6.0.
Buffers were prepared in deionized water and filtered through a 0.4 mm
filter. THP-1 cells (106 cells/ml in SBS buffer), were challenged with
CCL2 (50 ng/ml) at room temperature prior to sampling (200 ml). Cells
were immediately sedimented at 4 C˚ and 20,000 g. Clarified samples
were injected after two blank injections, and were compared with
nucleotide standards.
P2Y6-knockdown THP-1 cells
Lentiviral contructs using the pLKO.1-puro shRNA expression vector
targeting the human P2Y6 receptor were obtained from the Sigma
MISSION shRNA library. THP-1 cells (56104 cells/ml) were infected
with the lentiviral knockdown vectors (MOI 10) or non-target control
vectors for 72 h at 37 C˚ in a humidified 5% CO2 incubator. To generate
cells stably deficient in P2Y6, cells were selected with puromycin (1 mg/
ml) for 4 days. All cultures were maintained in THP-1 culture medium as
described above, supplemented with 1 mg/ml puromycin. P2Y6 mRNA
transcripts were quantified in THP-1 and knockdown cells using SYBR
Green-based quantitative PCR and the following primers: (sense) 59-
GCTCTCACTGTCATCGGCTT and (antisense) TCTGCCATTTGGC-
TGTGAGT-39. Clone 5 stable knockdown was generated with the
following shRNA sequence: 59-CCGGTGGTCCGCTTCCTCTTCTAT-
GCTCGAGCATAGAAGAGGAAGCGGACCATTTTTG-39.
Flow cytometry
105 THP-1, P2Y6-knockdown or scrambled control THP-1 cells were
washed with PBS before being labelled with a final concentration of
0.5 ng/ml phycoerythrin-conjugated anti-human-CCR2 or -mouse-IgG2a
K isotype control antibodies (Biolegend). Cells were labelled in PBS with
1% (w/v) BSA for 30 min at room temperature. For antagonist
experiments, THP-1 cells were pre-incubated with apyrase (2 U/ml),
MRS2578 (1 mM) or appropriate vehicle for 30 min prior to labelling.
Cells were washed twice in PBS and analysed on a BD Accuri C6. Gating
excluded debris, and at least 10,000 cells were analysed for each
experiment. FL2A represents fluorescence detection using a 585/25 band-
pass filter and excitation at 488 nm.
Statistical analysis
Data were analysed using Origin Pro 9.0 software (Origin Lab, USA).
Concentration–response curves were fitted assuming a Hill coefficient of
1. Hypothesis testing for experiments with paired datasets was performed
by means of paired Student’s t-test, and by ANOVA for experiments with
multiple datasets. Data are expressed as mean6s.e.m. of at least three
independent experiments.
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